Oral Rilzabrutinib, a Bruton Tyrosine Kinase Inhibitor, Showed Clinically Active and Durable Platelet Responses and Was Well-Tolerated in Patients with Heavily Pretreated Immune Thrombocytopenia

Category Primary study
JournalBlood
Year 2020
This article has no abstract
Epistemonikos ID: 99bc9cb7e18e0392723b0bd58471c5166181fce6
First added on: Feb 12, 2025